These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29325867)

  • 1. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies.
    Burghardt KJ; Seyoum B; Mallisho A; Burghardt PR; Kowluru RA; Yi Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Apr; 83():55-63. PubMed ID: 29325867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
    Ehret M; Goethe J; Lanosa M; Coleman CI
    J Clin Psychiatry; 2010 Oct; 71(10):1286-92. PubMed ID: 20441727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
    Citrome L; Kalsekar I; Baker RA; Hebden T
    Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics and diabetes mellitus.
    Lichiardopol R
    Rom J Intern Med; 2004; 42(2):301-12. PubMed ID: 15529621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms.
    Gonçalves P; Araújo JR; Martel F
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):1-16. PubMed ID: 25523882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.
    Volpato AM; Zugno AI; Quevedo J
    Braz J Psychiatry; 2013; 35(3):295-304. PubMed ID: 24142093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.
    Houseknecht KL; Robertson AS; Zavadoski W; Gibbs EM; Johnson DE; Rollema H
    Neuropsychopharmacology; 2007 Feb; 32(2):289-97. PubMed ID: 17035934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.
    Russell JM; Mackell JA
    CNS Drugs; 2001; 15(7):537-51. PubMed ID: 11510624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.
    Gentile S
    Drug Saf; 2006; 29(4):303-19. PubMed ID: 16569080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
    Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
    Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics].
    Scheen AJ; De Hert M
    Rev Med Liege; 2005; 60(5-6):455-60. PubMed ID: 16035311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance following continuous, chronic olanzapine treatment: an animal model.
    Chintoh AF; Mann SW; Lam TK; Giacca A; Remington G
    Schizophr Res; 2008 Sep; 104(1-3):23-30. PubMed ID: 18675538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.